Clinical Trial Update: An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab [Phase 3]

View source ↗

Summary

A clinical trial update describes an extension protocol for patients with relapsing-remitting multiple sclerosis who previously participated in Genzyme-sponsore…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED | Results posted: 2017-05-15